University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA.
J Cardiovasc Transl Res. 2013 Jun;6(3):329-45. doi: 10.1007/s12265-013-9449-0. Epub 2013 Feb 13.
Patients with diabetes mellitus (DM) are at high risk for several cardiovascular disorders such as coronary heart disease, stroke, peripheral arterial disease, and congestive heart failure. DM has reached epidemic proportions and its strong association with coronary artery disease is responsible for increased cardiovascular morbidity and mortality. DM patients are characterized by platelet hyperreactivity, which contribute to the enhanced atherothrombotic risk of these subjects. Several mechanisms are involved in the hyperreactive platelet phenotype characterizing DM patients. Furthermore, a large proportion of DM patients show inadequate response to standard antiplatelet treatments and high rate of adverse recurrent cardiovascular events despite compliance with standard antiplatelet treatment regimens. Therefore, new antiplatelet treatment regimens are warranted in DM patients to reduce their atherothrombotic risk. The present manuscript provides an overview on the current status of knowledge on platelet function profiles in patients with DM and therapeutic considerations.
糖尿病(DM)患者存在多种心血管疾病的高风险,如冠心病、中风、外周动脉疾病和充血性心力衰竭。DM 已达到流行程度,其与冠状动脉疾病的强烈关联导致心血管发病率和死亡率增加。DM 患者的特征是血小板高反应性,这导致这些患者的动脉粥样硬化血栓形成风险增加。几种机制参与了 DM 患者高反应性血小板表型的形成。此外,尽管符合标准抗血小板治疗方案,但很大一部分 DM 患者对标准抗血小板治疗的反应不足,且不良心血管事件的复发率较高。因此,DM 患者需要新的抗血小板治疗方案来降低其动脉粥样硬化血栓形成风险。本文综述了 DM 患者血小板功能谱的现状和治疗考虑。